The purpose of this study is to determine whether adjunctive cilostazol loading/maintenance
to standard treatment (aspirin, clopidogrel, and statin) is effective in reduction of major
adverse cardiovascular events, platelet activation, inflammation and myonecrosis in patients
with non-ST-elevation acute coronary syndrome (ACS)undergoing percutaneous coronary
intervention (PCI).